Soleus Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Soleus Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-97,547	Closed	-$9.95M	–	124
2023 Q2	$9.95M	Sell	97,547 -77,045	-44%	-$7.29M	1.11%	28
2023 Q1	$15.9M	Buy	+174,592	New	+$10.2M	1.64%	18

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Soleus Capital Management's RETA Position: Q3 2023 in Review

Soleus Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 97,547 shares — an estimated $9.95M sold.

Soleus Capital Management first reported a position in RETA in Q1 2023 and held it in 2 quarters. The position peaked at $15.9M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Soleus Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Soleus Capital Management sold 97,547 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $9.95M.
Soleus Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 2 quarters.
Soleus Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $15.9M in Q1 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.